1

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually incorporated by reference. From the foregoing, it will be evident that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

What claimed is:

1	1. A peptide consisting of five or more consecutive amino acid residues within one of
2	the following amino acid sequences:
3	VPGGSSCGTQARQGDPSTGPI (SEQ ID NO:);
4	RDKIPEEDRRKMQDKC (SEQ ID NO:)
5	AHVFHVKGSLQEESLRDKIPEEDRRKMQ (SEQ ID NO:); or
6	MQAPRELAVGID (SEQ ID NO:).
7	2. The peptide of claim 1, wherein the peptide consists of eight or more consecutive
8	amino acid residues.
9	3. The peptide of claim 1, wherein the peptide consists of ten or more consecutive
10	amino acid residues.
11	4. The peptide of claim 1, wherein the five or more consecutive amino acid residues
12	begin at the second, fourth, sixth, or eighth residue within one of the amino acid sequences.
13	5. The peptide of claim 1, further comprising a carrier that enhances the
14	immunogenicity of the peptide and, optionally, a linker between the peptide and the carrier.
15	6. The peptide of claim 5, wherein the carrier is keyhole limpet hemocyanin or
16	ovalbumin and the linker, when present, comprises an amino acid residue.
17	7. The peptide of claim 6, wherein the linker is a cysteine residue.
18	8. The peptide of claim 1, wherein the peptide consists of the amino acid sequence
19	CGTQARQGDPSTGPI (SEQ ID NO:).
20	9. A nucleic acid molecule that encodes a peptide of claim 1.
21	10. The nucleic acid molecule of claim 9, further comprising the sequence of an
22	expression vector.

11. A cell comprising the nucleic acid molecule of claim 10.

2324

- 12. The peptide of claim 1, wherein the peptide consists of one of the following 1 2 amino acid sequences: 3 VPGGSSCGTQARQGDPSTGPI (SEQ ID NO:); 4 RDKIPEEDRRKMQDKC (SEQ ID NO:) AHVFHVKGSLQEESLRDKIPEEDRRKMQ (SEQ ID NO:); or 5 MQAPRELAVGID (SEQ ID NO:). 6 7 AHVFHVKGSLQEES (SEQ ID NO:); 8 CGTQARQGDPSTGPI (SEQ ID NO:); CGTQARQGDPST (SEQ ID NO:); 9 10 RDKIPEEDRRKMQ (SEQ ID NO:); and GSLQEESLRDKIPEE (SEQ ID NO:). 11 12 13. The peptide of claim 12, further comprising a carrier that enhances the immunogenicity of the peptide and, optionally, a linker between the peptide and the carrier. 13 14. The peptide of claim 13, wherein the carrier is keyhole limpet hemocyanin or 14 ovalbumin and the linker, when present, comprises an amino acid residue. 15 15. The peptide of claim 14, wherein the linker is a cysteine residue. 16 16. A nucleic acid molecule that encodes a peptide of claim 12. 17 17. The nucleic acid molecule of claim 16, further comprising the sequence of an 18 19 expression vector. 20 18. A cell comprising the nucleic acid molecule of claim 17.
- 22 20. The antibody of claim 19, wherein the antibody is a monoclonal antibody.

19. An antibody that specifically binds Hsp70B'.

21. The antibody of claim 19, wherein the antibody has a relative titre index greater than one.

environment or a stressful substance, the method comprising performing an immunoassay in

26

- which proteins in or on the cell or proteins extracted from the cell are exposed to an antibody
- that specifically binds Hsp70B'.
- 3 33. The peptide of claim 5, wherein the carrier is a protein or a sugar.
- 4 34. The peptide of claim 13, wherein the carrier is a protein or a sugar.
- 5 35. The kit of claim 26, wherein the antibody is a monoclonal antibody.